DUBLIN–(BUSINESS WIRE)–The “Gene
Therapy – Technologies, Markets and Companies” report from Jain
PharmaBiotech has been added to Research and Markets’
The markets for gene therapy have been difficult to estimate as there
only a few approved gene therapy products Gene therapy markets are
estimated for the years 2016-2026.
The estimates are based on epidemiology of diseases to be treated with
gene therapy, the portion of those who will be eligible for these
treatments, competing technologies and the technical developments
anticipated in the next decades. In spite of some setbacks, the future
for gene therapy is bright. The markets for DNA vaccines are calculated
separately as only genetically modified vaccines and those using viral
vectors are included in the gene therapy markets.
Gene therapy technologies are described in detail including viral
vectors, nonviral vectors and cell therapy with genetically modified
vectors. Gene therapy is an excellent method of drug delivery and
various routes of administration as well as targeted gene therapy are
described. There is an introduction to technologies for gene suppression
as well as molecular diagnostics to detect and monitor gene expression.
Gene editing technologies such as CRISPR-Cas9 and CAR-T cell therapies
are also included.
Clinical applications of gene therapy are extensive and cover most
systems and their disorders. Full chapters are devoted to genetic
syndromes, cancer, cardiovascular diseases, neurological disorders and
viral infections with emphasis on AIDS. Applications of gene therapy in
veterinary medicine, particularly for treating cats and dogs, are
Research and development is in progress in both the academic and the